A GLP-1/GIP drug helped adults with type 1 diabetes lose weight in a 16-week trial
In a phase 2 trial published Oct. 28, 2026, in Diabetes Care, adults with type 1 diabetes and overweight or obesity who took acmopatide lost 3.3% to 6.7% of their body weight…